Elsevier

Bone

Volume 45, Issue 4, October 2009, Pages 677-681
Bone

Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats

https://doi.org/10.1016/j.bone.2009.05.024Get rights and content

Abstract

The osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) axis is thought to be involved in the upregulation of bone turnover following sex steroid deficiency. Here, we investigated the effects of orchiectomy (ORX) on bone turnover and free soluble RANKL (sRANKL) in aged rats. Free, bioactive sRANKL is a critical determinant and key mediator for survival and activity of mature osteoclasts. Thirty-three 9-month-old male Fischer-344 rats were either ORX or sham-operated (SHAM). Following in vivo fluorochrome labeling, vehicle (ricinus oil/benzyl benzoate)-treated SHAM and vehicle- or testosterone undecanoate (T, 6 mg/kg s.c. once weekly)-treated ORX rats (n = 8–9 each) were killed 2 months after surgery. Vehicle-treated ORX rats showed lower seminal vesicle weight, loss of proximal tibial trabecular bone mineral density, and reduced cortical thickness at the tibial shaft as measured by peripheral quantitative computed tomography relative to SHAM controls. Bone loss in vehicle-treated ORX rats was associated with enhanced bone turnover as evidenced by increases in tibial cancellous bone formation rate, osteoclast numbers, urinary excretion of calcium and deoxypyridinoline, and serum osteocalcin. T treatment of ORX rats restored seminal vesicle weight to SHAM control levels, and completely protected against post-ORX bone loss by suppressing bone turnover. Free sRANKL concentrations in bone marrow supernatants harvested from the proximal femur were about 3-fold higher in vehicle-treated ORX relative to SHAM rats, and returned to SHAM control levels in T-treated ORX rats. mRNA abundance of matrix metalloproteinase-14 (MMP-14) in bone marrow was 4-fold higher in vehicle-treated ORX rats relative to SHAM rats. T treatment of ORX rats suppressed MMP-14 mRNA expression to SHAM control levels. We conclude that orchiectomy increases the concentration of free sRANKL in bone marrow of aged rats. In addition, increased shedding of membrane-bound RANKL by MMP-14 may be a pivotal mechanism resulting in augmented free sRANKL concentrations in the bone marrow environment after androgen withdrawal.

Introduction

Declining bioavailable sex steroid levels are a major risk factor for osteoporosis in men [1], [2]. The important role of androgens in the maintenance of an adult male skeleton is documented by the fact that withdrawal of androgens by orchiectomy (ORX) or androgen blockade induces high turnover osteopenia in humans, aged mice, and aged rats [3], [4], [5], [6], [7], [8], [9], [10], [11]. Although still a matter of debate, several lines of evidence from clinical and experimental studies suggest that the suppressive effect of androgens on cancellous and endocortical bone turnover may be mediated indirectly via aromatization of androgens into estrogens [2], [9], [11], [12], [13], [14].

The aged ORX rat model has been very well described in terms of its phenotype [8], [9], [11]. However, the molecular pathogenesis of androgen deficiency-induced bone loss is still poorly understood. The OPG/RANKL system has been proposed as a potential mediator of sex steroid deficiency-induced bone loss. RANKL has been identified as an essential cytokine for osteoclast differentiation and activation [15], [16], and OPG represents its naturally occurring inhibitor [17]. RANKL is produced by cells of the stromal cell lineage, activated T lymphocytes, but also B lymphocytes [16]. The OPG/RANKL ratio is an essential determinant of osteoclast cell biology and bone resorption [18], [19]. Sex steroids regulate the expression of OPG and RANKL in vitro [19]. Orchiectomy of male rats increased RANKL mRNA expression in bone [20], and conditional ablation of the androgen receptor (AR) in mice upregulated osteoblast RANKL mRNA expression [21]. Vice versa, estradiol decreased the OPG/RANKL mRNA ratio and increased trabecular bone mineral density (BMD) in vertebrae of male ORX mice [22]. A recent flow cytometric analysis of bone marrow aspirates demonstrated that estrogen deficiency in women upregulates the membrane expression of RANKL protein on alkaline phosphatase-positive osteoblastic cells, CD3-positive T cells, and CD20-positive B cells [23]. Similarly, in men who underwent suppression of sex steroids using a gonadotropin-releasing hormone agonist in combination with an aromatase inhibitor, a non-significant trend for increased RANKL mRNA levels was observed in alkaline phosphatase-positive osteoblastic cells obtained from bone marrow aspirates [24]. However, unambiguous clinical or experimental evidence linking alterations in the OPG/RANKL axis with androgen withdrawal-induced bone loss in vivo is lacking.

It was the aim of this study to investigate further the role of the OPG/RANKL system in ORX-induced osteopenia in aged rats. So far, the evaluation of the OPG/RANKL axis in rats has been hampered by the fact that there is no commercially available immunoassay for rat OPG. To circumvent the problem that OPG cannot be measured at the protein level in rats, we used a novel rat- and mouse-specific immunoassay to assess free sRANKL in serum and bone marrow of aged ORX rats. Free sRANKL is the bioactive form of sRANKL that is not bound to OPG and can access its receptor RANK. Free sRANKL is either produced by immune cells as a primary secreted form [16], or results from shedding of membrane-bound RANKL by matrix metalloproteinase 14 (MMP-14) or by a disintegrin and metalloproteinase (ADAM) 10 [25]. Although the physiological function of RANKL shedding from osteoblastic cells is still controversial, free sRANKL may be the critical determinant of osteoclast activation and survival, and it accurately reflected the state of bone resorption in OPG deficient mice [26]. In the current study, we tested the hypothesis that orchiectomy may upregulate free sRANKL in the bone microenvironment of aged rats.

Section snippets

Animal procedures

All animal procedures were approved by the Ethical Committee of the University of Munich and the local government authorities. Thirty-three 9-month-old male Fischer-344 rats (Charles River) weighing about 400 g were used for this experiment. Eight rats served as baseline controls. The remaining rats were either bilaterally ORX under ether anesthesia or sham-operated (SHAM, skin incision at the scrotum). The animals were kept in pairs at 24 °C with a 12 h/12 h light/dark cycle. All rats received

Results

As expected, seminal vesicle weight was profoundly reduced in ORX relative to SHAM controls, 2 months post-ORX (Fig. 1A). In agreement with our earlier results [11], [31], weekly subcutaneous injection of 6 mg/kg T in ricinus oil-benzyl benzoate normalized seminal vesicle organ weight (Fig. 1A), showing that this is a physiological dose of testosterone. pQCT analysis of the tibiae revealed reduced trabecular BMD at the proximal tibia (Fig. 1B), and reduced cortical thickness of the tibial shaft

Discussion

In accordance with previous data from our laboratory and other groups, our study has shown that androgen withdrawal induces high turnover cancellous and cortical bone osteopenia in aged, nongrowing rats, 2 months post-ORX [3], [4], [5], [6], [7], [8], [9], [10], [11]. The 2-month time point in the current experiment was chosen on the basis that the increase in bone turnover in aged ORX rats peaks 2 months after surgery [9]. Supplementation of ORX rats with T at a physiological dose of

Acknowledgments

This research was supported by a grant from Deutsche Forschungsgemeinschaft to RGE (ER 223/1–3). The authors wish to thank Claudia Bergow and Sieglinde Hirmer for excellent technical assistance. Testosterone undecanoate was a gift of Dr. Uwe Kollenkirchen (Bayer-Schering, Berlin, Germany). The free sRANKL assays were a gift of Dr. Gerhard Hawa (Biomedica Medizinprodukte GmbH and Co KG, Divischgasse 4, 1210 Vienna, Austria).

References (36)

  • L. Katznelson et al.

    Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism

    J. Clin. Endocrinol. Metab.

    (1996)
  • J.J. Stepan et al.

    Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling

    J. Clin. Endocrinol. Metab.

    (1989)
  • R.S. Weinstein et al.

    The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage

    Endocrinology

    (1997)
  • D. Vanderschueren et al.

    Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency

    Endocrinology

    (1992)
  • R.G. Erben et al.

    Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study

    J. Bone Miner. Res.

    (2000)
  • T. Diamond et al.

    The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma—longitudinal evaluation and response to intermittent cyclic etidronate therapy

    Cancer

    (1998)
  • N.S. Reim et al.

    Cortical bone loss in androgen-deficient aged male rats is mainly caused by increased endocortical bone remodeling

    J. Bone Miner. Res.

    (2008)
  • A. Falahati-Nini et al.

    Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men

    J. Clin. Invest.

    (2000)
  • Cited by (0)

    Sources of funding: Deutsche Forschungsgemeinschaft ER223/1–3.

    View full text